Last reviewed · How we verify

NCT05826184

Time Restricted Eating With or Without a Fiber Supplement for Weight Management in Pediatric Cancer Survivors

Completed NA Last updated 3 October 2025
What this trial tests

NA trial testing Time restircted eating in Weight, Body in 13 participants. Completed in 1 July 2025.

Timeline
17 November 2023
Primary endpoint
1 July 2025
1 July 2025

Quick facts

Lead sponsorUniversity of Illinois at Chicago
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment13
Start date17 November 2023
Primary completion1 July 2025
Estimated completion1 July 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Illinois at Chicago

Who can join

Adults 18 to 39, any sex, with Weight, Body. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to address a critical gap in pediatric oncology survivorship care by exploring innovative solutions to addressing obesity and its comorbidities in pediatric cancer survivors. The majority (99%) of pediatric cancer survivors will develop severe chronic health conditions by age 50, with 96% developing at least one severe/disabling, life threating or fatal chronic health condition. Obesity, cardiovascular, and metabolic diseases are the most common treatment-related late effects among pediatric cancer survivors. Improving diet and reducing obesity has the potential to dramatically improve the quality of life and long-term health of pediatric cancer survivors. Utilization of a prebiotic fiber supplement along with TRE amy improve the gut microbiome, short-chain fatty acid synthesis, and hunger hormones to further improve weight loss with TRE and a greater decrease in cardiometabolic risk. The aims of this study are to test the safety, feasibility, and acceptability of 8-h TRE or 8-h TRE with a fiber supplement among young adult (YA) pediatric cancer survivors. The investigators further strive to examine the preliminary efficacy of TRE on body weight, body composition, glucose regulation, and cardiovascular risk markers. Data obtained will be used to inform a larger efficacy trial of TRE among adolescent and young adult pediatric cancer survivors. Given that a majority of pediatric cancer survivors will develop severe chronic health conditions by age 50, with 96% developing at least one severe/disabling, life threating or fatal chronic health condition exploring accessible nutritional strategies to improve long term health trajectory of 70,000+ AYA diagnosed with cancer each year in the United States. This study of TRE will provide important preliminary evidence of the benefits of this nutrition therapy for YA pediatric cancer survivors. The long-term goal of this line of inquiry is to improve both short and long-term outcomes for YA pediatric cancer survivors.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Time-Restricted Eating and Prebiotic Supplementation Demonstrate Feasibility and Acceptability in Young Adult Pediatric Cancer Survivors: A Randomized Controlled Pilot Trial.
    Cares K, Lima Oliveira M, Bryner A, Man B, et al · · 2025 · PMID 41156558 · DOI 10.3390/nu17203306

Verify or expand the search:

Other recruiting trials for Weight, Body

Currently open trials in the same condition.

Other University of Illinois at Chicago trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05826184.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing